Trial · NCT03292484
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | AR101 | TEAEs | 866 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | AR101 | TESAEs | 42 | Participants | |
| Number of Participants With Premature Discontinuation of AR101 Dosing Due to TEAEs | AR101 | 53 | Participants | ||
| Number of Participants With Premature Discontinuation of AR101 Dosing Due to Chronic/Recurrent Gastrointestinal TEAEs | AR101 | 25 | Participants | ||
| Number of Participants With TEAEs That Led to a Change in Treatment Regimen | AR101 | TEAEs requiring dose interruption of study treatment | 669 | Participants | |
| Number of Participants With TEAEs That Led to a Change in Treatment Regimen | AR101 | TEAEs requiring dose reduction of study treatment | 167 | Participants | |
| Number of Participants With TEAEs That Led to Early Withdrawal | AR101 | 27 | Participants | ||
| Number of Participants Who Experienced a Treatment-emergent Anaphylactic Reaction | AR101 | 192 | Participants | ||
| Number of Participants With Use of Epinephrine as a Rescue Medication | AR101 | 234 | Participants | ||
| Number of Participants Who Experienced Accidental or Non-accidental Food Allergy Episodes | AR101 | Accidental Food Allergy Episodes | 208 | Participants | |
| Number of Participants Who Experienced Accidental or Non-accidental Food Allergy Episodes | AR101 | Non-accidental Food Allergy Episodes | 35 | Participants | |
| Number of Participants With TEAEs Following Accidental or Non-accidental Exposure to Peanut and Other Allergenic Foods | AR101 | 227 | Participants | ||
| Number of Participants With Eosinophilic Esophagitis (EoE) | AR101 | 7 | Participants | ||
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | OLFC: Tolerated a single highest dose of at least 300 mg | 98.6 | 95% Confidence Interval 97.2 to 99.5 | percentage of participants |
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | OLFC: Tolerated a single highest dose of at least 600 mg | 94.2 | 95% Confidence Interval 91.8 to 96.1 | percentage of participants |
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | OLFC: Tolerated a single highest dose of at least 1000 mg | 78.7 | 95% Confidence Interval 74.9 to 82.2 | percentage of participants |
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | OLFC: Tolerated a single highest dose of at least 2000 mg | 55.9 | 95% Confidence Interval 51.5 to 60.2 | percentage of participants |
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | DBPCFC: Tolerated a single highest dose of at least 3 mg | 100.0 | 95% Confidence Interval 98.3 to 100.0 | percentage of participants |
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | DBPCFC: Tolerated a single highest dose of at least 10 mg | 100.0 | 95% Confidence Interval 98.3 to 100.0 | percentage of participants |
| Percentage of Participants Tolerating Each Challenge Dose in the Open-label Food Challenge (OLFC) and the Double-blind, Placebo-Controlled Food Challenge (DBPCFC) | AR101 | DBPCFC: Tolerated a single highest dose of at least 30 mg | 99.5 | 95% Confidence Interval 97.4 to 100.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03292484/results